Icatibant Aguettant

Icatibant, the active ingredient in Icatibant Aguettant, is a bradykinin B2 receptor antagonist presented as a sterile solution for injection for subcutaneous use. It is indicated for the treatment of acute attacks of hereditary angioedema type I and type II, providing rapid reduction of swelling in affected patients.

GNH USA supplies Icatibant Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with European Union marketing authorisation requirements and is manufactured under GMP conditions, ensuring consistent potency and safety.

Icatibant is used to manage hereditary angioedema, a disorder driven by excessive bradykinin activity.

Acute hereditary angioedema type I attacks: rapid reduction of swelling and pain during an episode. Acute hereditary angioedema type II attacks: fast alleviation of edema and associated discomfort. Hereditary angioedema of any type: provides prompt symptom control when administered at onset of an attack.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects: - Injection site pain - Redness or swelling at injection site - Headache

Serious or Rare Side Effects: - Anaphylaxis - Severe angioedema unrelated to HAE - Hypotension

When prescribing Icatibant, several precautionary measures should be considered to ensure safe use.

Renal impairment: use with caution and monitor response. Hepatic impairment: consider dose adjustment and observe for accumulation. Pregnancy: safety not established; prescribe only if benefit outweighs potential risk. Breastfeeding: unknown excretion; evaluate risk versus benefit before use. Known hypersensitivity: contraindicated in patients with allergy to icatibant or formulation components. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines, influencing bradykinin pathways or masking clinical signs.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels and exacerbate swelling. - Other bradykinin B2 receptor antagonists: additive antagonism could lead to unexpected effects. - Angiotensin receptor blockers: potential for enhanced bradykinin‑mediated reactions.

Moderate Interactions (Monitor Closely): - Corticosteroids: may conceal signs of infection at injection site. - Antihistamines: could alter assessment of allergic reactions. - Diuretics: monitor blood pressure due to possible additive hypotensive effect.